Journal of the advanced practitioner in oncology最新文献

英文中文

Sequencing Therapies in Renal Cell Carcinoma 肾癌的测序治疗

Journal of the advanced practitioner in oncology

Pub Date : 2019-04-01 DOI: 10.6004/jadpro.2019.10.3.12

引用次数: 0

Therapeutic Advances in Prostate Cancer 癌症治疗进展

Journal of the advanced practitioner in oncology

Pub Date : 2019-04-01 DOI: 10.6004/jadpro.2019.10.3.13

引用次数: 0

JADPRO Live 2018: Bringing Clarity to Complexity JADPRO Live 2018:为复杂性带来清晰度

Journal of the advanced practitioner in oncology

Pub Date : 2019-04-01 DOI: 10.6004/jadpro.2019.10.3.1

引用次数: 0

Differential Diagnosis and Testing for Hematologic Malignancies 血液系统恶性肿瘤的鉴别诊断和检测

Journal of the advanced practitioner in oncology

Pub Date : 2019-04-01 DOI: 10.6004/jadpro.2019.10.3.14

引用次数: 0

Multiple Myeloma 多发性骨髓瘤

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/jadpro.2019.10.2.16

Arnp Josh Epworth

1995 Subcutaneous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma: Part 2 Safety and E cacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) Ajai Chari, MD, Maria-Victoria Mateos, MD, PhD, Niels W. C. J. van de Donk, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD, DSc, Lotfi Benboubker, MD, Hareth Nahi, MD, PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L. Clemens, PhD, Andrew Farnsworth, Visit http://www.bloodjournal.org/content/132/ Suppl_1/1995 for a complete list of contributor affiliations and full graphics. Introduction: man IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action. DARA (16 mg/kg administered intravenously [IV]) is approved in many countries as monotherapy and in combination with standard of care (SOC) treatment regimens for patients with relapsed/refractory (RR) multiple myeloma (MM) and newly diagnosed MM. Three phase 3 studies have now demonstrated that DARA in combination with SOC treatment doubles complete response (CR) rates, triples minimal residual disease-negative rates, and reduces the risk of progression or death by at least 50% vs SOC alone. The median durations of the first, second, and subsequent DARA IV infusions are 7.0, 4.3, and 3.4 hours, respectively. To determine whether the duration of infusion can be shortened without coman open-label, multicenter, phase 1b clinical trial (PAVO; NCT02519452) was conducted to evaluate a subcutaneous (SC) formulation of DARA with recombinant human hyaluronidase enzyme PH20 ogy, Halozyme, Inc.) in patients with RRMM. Part 1 of the study revealed that a mix-and-deliver SC administration was well tolerated, with low rates of infusion-related reactions (IRRs) and similar stract 1149). Here, we present updated safety and where a concentrated, pre-mixed SC co-formulation of DARA and rHuPH20 (DARA SC) was evaluated in patients with RRMM. Methods: ceived ≥2 prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD). In Part 2 of the study, a concentrated co-formulation of DARA (1,800 mg) and rHuPH20 (30,000 U; in 15 mL) in a single, premixed vial was administered over 3 to 5 minutes by manual SC injection into the abdomen. DARA SC was given QW during Cycles 1-2, Q2W during Cycles 3-6, and Q4W thereafter in 28-day cycles. Preand/or post infusion medications included acetaminophen, diphenhydramine, montelukast, and methylprednisolone. Co-primary endpoints were safety and Ctrough QW dosing. Secondary endpoints included the overall response rate (ORR) and CR rate according to the International Myeloma Working Group response criteria. Results: ber 13, 2017, 25 patients were enrolled in Part 2 of the study. Patients received a median of 3 (range: 2-9) prior lines of therapy, with 56% double refractory to both PI and IMiD. No treatment discontinuations occurred due to treatment-emergent adverse events (TEAEs). The most common (≥20%) T

1995复发性或难治性多发性骨髓瘤患者皮下注射Daratumumab：开放标签、多中心、1b期研究（PAVO）的第2部分安全性和疗效更新医学博士Ajai Chari、医学博士Maria Victoria Mateos、博士Niels W.C.J.van de Donk、医学博士Jonathan L.Kaufman、医学博士Philippe Moreau、医学博士Albert Oriol、医学博士Torben Plesner、DSc、医学博士Lotfi Benboubker、医学博士Hareth Nahi、医学博士Jie Tang，Peter Hellemans，Brenda Tromp，理学硕士，Pamela L.Clemens，博士，Andrew Farnsworth，访问http://www.bloodjournal.org/content/132/Suppl_1/1995提供了一份完整的投稿人名单和完整的图片。人IgGκ抗CD38单克隆抗体具有直接对肿瘤和免疫调节作用机制。DARA（16 mg/kg静脉注射[IV]）在许多国家被批准为单一疗法，并与标准护理（SOC）治疗方案相结合，用于复发/难治性（RR）多发性骨髓瘤（MM）和新诊断的MM患者。三项3期研究现已证明，DARA与SOC治疗相结合使完全缓解（CR）率翻倍，使最小残留疾病阴性率增加三倍，并将进展或死亡风险比单独SOC降低至少50%。第一次、第二次和随后的DARA IV输注的中位持续时间分别为7.0、4.3和3.4小时。为了确定输注持续时间是否可以在没有coman开放标签的情况下缩短，进行了多中心1b期临床试验（PAVO；NCT02519452），以评估在RRMM患者中使用重组人透明质酸酶PH20-ogy（Halozyme，股份有限公司）的DARA皮下（SC）制剂。该研究的第1部分显示，混合和递送SC给药具有良好的耐受性，输注相关反应（IRRs）发生率较低，类似情况1149）。在这里，我们介绍了最新的安全性，并在RRMM患者中评估了DARA和rHuPH20的浓缩、预混合SC联合制剂（DARA SC）。方法：接受≥2种既往治疗，包括蛋白酶体抑制剂（PI）和免疫调节药物（IMiD）。在该研究的第2部分中，通过将SC手动注射到腹部，在3至5分钟内将DARA（1800 mg）和rHuPH20（30000 U；15 mL）在单个预混小瓶中的浓缩共制剂给药。DARA SC在周期1-2期间给予QW，在周期3-6期间给予Q2W，此后在28天周期给予Q4W。输注前后药物包括对乙酰氨基酚、苯海拉明、孟鲁司特和甲基强的松龙。共同的主要终点是安全性和Ctrough QW给药。次要终点包括根据国际骨髓瘤工作组反应标准的总有效率（ORR）和CR率。结果：2017年12月13日，25名患者被纳入本研究的第2部分。患者接受了中位数为3（范围：2-9）的既往治疗，其中56%的患者对PI和IMiD都有双重难治性。没有因治疗突发不良事件（TEAE）而中断治疗。最常见（≥20%）的TEAE包括淋巴细胞减少症（32%）、血小板减少症（24%）、疲劳、乏力、背痛、腹泻、恶心、头痛和病毒性上呼吸道感染（各20%）。DARA SC的IRRs发生率（16%）和严重程度（主要为1-2级）较低，大多数发生在第1周期第1天，未观察到因IRRs而中断。《多发性骨髓瘤杂志2019年临床肿瘤学》报道了短暂性3级高血压；10（补充2）：4-9https://doi.org/10.6004/jadpro.2019.10.2.16这是Cr ea tiv e C om m on s A ttr ibu tio n n on-C om m cia l n on-d er iva tiv e l ice ns e的三个部分，即它的非结构化无nco m er cia l A和非私有化、三个部分、一个在一个y m d ium中的操作过程，以及它的内部或外部。

{"title":"Multiple Myeloma","authors":"Arnp Josh Epworth","doi":"10.6004/jadpro.2019.10.2.16","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.2.16","url":null,"abstract":"1995 Subcutaneous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma: Part 2 Safety and E cacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) Ajai Chari, MD, Maria-Victoria Mateos, MD, PhD, Niels W. C. J. van de Donk, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD, DSc, Lotfi Benboubker, MD, Hareth Nahi, MD, PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L. Clemens, PhD, Andrew Farnsworth, Visit http://www.bloodjournal.org/content/132/ Suppl_1/1995 for a complete list of contributor affiliations and full graphics. Introduction: man IgGκ anti-CD38 monoclonal antibody with a direct on-tumor and immunomodulatory mechanism of action. DARA (16 mg/kg administered intravenously [IV]) is approved in many countries as monotherapy and in combination with standard of care (SOC) treatment regimens for patients with relapsed/refractory (RR) multiple myeloma (MM) and newly diagnosed MM. Three phase 3 studies have now demonstrated that DARA in combination with SOC treatment doubles complete response (CR) rates, triples minimal residual disease-negative rates, and reduces the risk of progression or death by at least 50% vs SOC alone. The median durations of the first, second, and subsequent DARA IV infusions are 7.0, 4.3, and 3.4 hours, respectively. To determine whether the duration of infusion can be shortened without coman open-label, multicenter, phase 1b clinical trial (PAVO; NCT02519452) was conducted to evaluate a subcutaneous (SC) formulation of DARA with recombinant human hyaluronidase enzyme PH20 ogy, Halozyme, Inc.) in patients with RRMM. Part 1 of the study revealed that a mix-and-deliver SC administration was well tolerated, with low rates of infusion-related reactions (IRRs) and similar stract 1149). Here, we present updated safety and where a concentrated, pre-mixed SC co-formulation of DARA and rHuPH20 (DARA SC) was evaluated in patients with RRMM. Methods: ceived ≥2 prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD). In Part 2 of the study, a concentrated co-formulation of DARA (1,800 mg) and rHuPH20 (30,000 U; in 15 mL) in a single, premixed vial was administered over 3 to 5 minutes by manual SC injection into the abdomen. DARA SC was given QW during Cycles 1-2, Q2W during Cycles 3-6, and Q4W thereafter in 28-day cycles. Preand/or post infusion medications included acetaminophen, diphenhydramine, montelukast, and methylprednisolone. Co-primary endpoints were safety and Ctrough QW dosing. Secondary endpoints included the overall response rate (ORR) and CR rate according to the International Myeloma Working Group response criteria. Results: ber 13, 2017, 25 patients were enrolled in Part 2 of the study. Patients received a median of 3 (range: 2-9) prior lines of therapy, with 56% double refractory to both PI and IMiD. No treatment discontinuations occurred due to treatment-emergent adverse events (TEAEs). The most common (≥20%) T","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"4 - 6"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46483694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leukemias and Lymphomas 白血病和淋巴瘤

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/jadpro.2019.10.2.18

S. Kurtin, Anp-C, Aocn

引用次数: 0

Diagnostic Snapshot: A Patient With Gastrointestinal Symptoms and Eosinophilia 诊断快照:一个有胃肠道症状和嗜酸性粒细胞增多的病人

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/jadpro.2019.10.2.8

Rashida Taher, S. Kurtin

© 2019 Harborside Press® J Adv Pract Oncol 2019;10(2):180–183 HISTORY Mr. C, a 63-year-old Cape Verdean male, was referred to the hematology/oncology office for evaluation of eosinophilia in May 2017. The eosinophilia was first documented in December 2003 by his primary care provider. In March 2005, Mr. C underwent colonoscopy for mild rectal bleeding and was incidentally found to have eosinophilic colitis. Stool ova and parasite testing was negative. Because he was asymptomatic at the time, no treatment was initiated. One year later (2006), Mr. C developed dyspepsia in the presence of continued eosinophilia. An upper endoscopy with biopsy was performed, revealing Helicobacter pylori–positive chronic active gastritis. He was treated with a 14-day course of triple therapy. Follow-up H. pylori antigen stool test was negative. In April 2017, Mr. C developed recurrent abdominal pain for which an endoscopy and colonoscopy were performed. Biopsies of the cecum, splenic flexure, and sigmoid colon were significant for eosinophilic infiltrates. A complete blood count demonstrated eosinophilia with normal hemoglobin, white blood cell, and platelet counts. Stool testing using an extended gastrointestinal panel was unremarkable. It was at this time that Mr. C was referred to hematology/oncology. Past medical history was significant for diabetes, hypertension, and hyperlipidemia. Mr. C did not have a history of asthma or food/drug allergies. His medications included amlodipine at 25 mg, aspirin at 325 mg, glipizide at 5 mg, metformin at 1,000 mg, and pravastatin at 80 mg. A review of systems revealed that Mr. C was negative for any fevers, night sweats, weight loss, rash/pruritus, dyspnea, or diarrhea. A physical exam showed normal vital signs, no palpable adenopathy, normal cardiopulmonary exam, no hepatosplenomegaly, no palpable masses, and no skin rashes or nodules. A computed tomography scan of the chest, abdomen, and pelvis was unremarkable. No adenopathy, masses, or hepatosplenomegaly were noted. Mr. C’s labs are shown in Tables 1 and 2. Th is ar tic le is dis tri bu te d u nd er th e t er m s o f t he Cr ea tiv e C om m on s A ttr ibu tio n N on -C om m er cia l L ice ns e, wh ich pe rm its

©2019 Harborside Press®J Adv Pract Oncol 2019；10（2）:180-183病史C先生，63岁，佛得角男性，于2017年5月被转诊至血液学/肿瘤学办公室进行嗜酸性粒细胞增多症评估。2003年12月，他的初级保健提供者首次记录了嗜酸性粒细胞增多症。2005年3月，C先生因轻度直肠出血接受了结肠镜检查，偶然发现患有嗜酸性结肠炎。粪便卵和寄生虫检测呈阴性。因为他当时没有症状，所以没有开始治疗。一年后（2006年），C先生在持续的嗜酸性粒细胞增多的情况下出现消化不良。进行了带活检的上内镜检查，发现幽门螺杆菌阳性的慢性活动性胃炎。他接受了为期14天的三联治疗。随访幽门螺杆菌抗原粪便检测结果为阴性。2017年4月，C先生出现复发性腹痛，为此进行了内窥镜检查和结肠镜检查。盲肠、脾曲和乙状结肠的活检对嗜酸性粒细胞浸润有重要意义。全血细胞计数显示嗜酸性粒细胞增多，血红蛋白、白细胞和血小板计数正常。使用扩展胃肠道小组进行大便测试并不显著。正是在这个时候，C先生被转诊到血液学/肿瘤学。既往病史对糖尿病、高血压和高脂血症具有重要意义。C先生没有哮喘或食物/药物过敏史。他的药物包括25 mg的氨氯地平、325 mg的阿司匹林、5 mg的格列吡嗪、1000 mg的二甲双胍和80 mg的普伐他汀。系统审查显示，C先生发烧、盗汗、体重减轻、皮疹/瘙痒、呼吸困难或腹泻均为阴性。体检显示生命体征正常，无明显腺病，心肺检查正常，无肝脾肿大，无明显肿块，无皮疹或结节。胸部、腹部和骨盆的计算机断层扫描并不明显。未发现腺病、肿块或肝脾肿大。C先生的实验室如表1和表2所示。这是对Cr ea tive C om m on s A ttr ibu tio n n on-C om m er cia l ice es e的三次分解，其结果是

{"title":"Diagnostic Snapshot: A Patient With Gastrointestinal Symptoms and Eosinophilia","authors":"Rashida Taher, S. Kurtin","doi":"10.6004/jadpro.2019.10.2.8","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.2.8","url":null,"abstract":"© 2019 Harborside Press® J Adv Pract Oncol 2019;10(2):180–183 HISTORY Mr. C, a 63-year-old Cape Verdean male, was referred to the hematology/oncology office for evaluation of eosinophilia in May 2017. The eosinophilia was first documented in December 2003 by his primary care provider. In March 2005, Mr. C underwent colonoscopy for mild rectal bleeding and was incidentally found to have eosinophilic colitis. Stool ova and parasite testing was negative. Because he was asymptomatic at the time, no treatment was initiated. One year later (2006), Mr. C developed dyspepsia in the presence of continued eosinophilia. An upper endoscopy with biopsy was performed, revealing Helicobacter pylori–positive chronic active gastritis. He was treated with a 14-day course of triple therapy. Follow-up H. pylori antigen stool test was negative. In April 2017, Mr. C developed recurrent abdominal pain for which an endoscopy and colonoscopy were performed. Biopsies of the cecum, splenic flexure, and sigmoid colon were significant for eosinophilic infiltrates. A complete blood count demonstrated eosinophilia with normal hemoglobin, white blood cell, and platelet counts. Stool testing using an extended gastrointestinal panel was unremarkable. It was at this time that Mr. C was referred to hematology/oncology. Past medical history was significant for diabetes, hypertension, and hyperlipidemia. Mr. C did not have a history of asthma or food/drug allergies. His medications included amlodipine at 25 mg, aspirin at 325 mg, glipizide at 5 mg, metformin at 1,000 mg, and pravastatin at 80 mg. A review of systems revealed that Mr. C was negative for any fevers, night sweats, weight loss, rash/pruritus, dyspnea, or diarrhea. A physical exam showed normal vital signs, no palpable adenopathy, normal cardiopulmonary exam, no hepatosplenomegaly, no palpable masses, and no skin rashes or nodules. A computed tomography scan of the chest, abdomen, and pelvis was unremarkable. No adenopathy, masses, or hepatosplenomegaly were noted. Mr. C’s labs are shown in Tables 1 and 2. Th is ar tic le is dis tri bu te d u nd er th e t er m s o f t he Cr ea tiv e C om m on s A ttr ibu tio n N on -C om m er cia l L ice ns e, wh ich pe rm its","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"180 - 183"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42994756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Benefits of Nuts for Cancer Prevention 坚果对癌症预防的益处

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/JADPRO.2019.10.2.1

P. Viale

The American Cancer Society estimates 101,420 new cases of colon cancer and 44,180 new cases of rectal cancer in the United States this year (American Cancer Society, 2019). Colorectal cancer remains the third leading cause of death from cancer in both sexes, with approximately 51,020 deaths expected this year (American Cancer Society, 2019). And disturbingly, although the overall death rate has dropped, the death rate for younger people (aged 55 or younger) has increased 1% per year from 2007 through 2016 (American Cancer Society, 2019). These statistics are sobering to me, as this is a cancer that is largely preventable through rigorous screening. It is one of the cancers we can successfully do something about. And yet, we still see colorectal cancer. For this reason, I am always interested in data that show variables that may reduce colorectal cancer and death in patients with this disease.

美国癌症协会估计，今年美国将有101420例结肠癌新病例和44180例直肠癌新病例。(美国癌症协会，2019年)结直肠癌仍然是男女癌症死亡的第三大原因，预计今年将有大约51,020人死亡(美国癌症协会，2019年)。令人不安的是，尽管总体死亡率有所下降，但从2007年到2016年，年轻人(55岁或以下)的死亡率每年增长1%(美国癌症协会，2019年)。这些数据让我清醒，因为这种癌症在很大程度上是可以通过严格的筛查来预防的。这是我们可以成功治疗的癌症之一。然而，我们仍然看到结直肠癌。出于这个原因，我总是对显示可能减少结直肠癌和患者死亡率的变量的数据感兴趣。

引用次数: 2

Immuno-Oncology Essentials: An Overview 免疫肿瘤学要点:概述

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/jadpro.2019.10.2.9

Brianna W. Hoffner

© 2019 HarborsideTM We are honored to share with you this supplement entitled ImmunoOncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events. Immunotherapy with immune checkpoint inhibitors (ICIs) has remarkably revolutionized cancer care, improving outcomes for many patients with diverse tumor types. The awarding of the 2018 Nobel Prize in Medicine to two of the scientists involved with ICI development, James P. Allison and Tasuku Honjo, is a testament to this fact. The impact of ICIs is likely to continue to expand, as these therapies are used in an ever-growing

©2019 harborsiddetm我们很荣幸与您分享这份题为《免疫肿瘤治疗要点:免疫相关不良事件的主动管理》的增刊。免疫检查点抑制剂(ICIs)的免疫治疗已经显著地改变了癌症治疗，改善了许多不同肿瘤类型患者的预后。2018年诺贝尔医学奖授予参与ICI开发的两位科学家詹姆斯·p·艾利森(James P. Allison)和本庶寿(Tasuku Honjo)就是这一事实的证明。ici的影响可能会继续扩大，因为这些疗法在越来越多的疾病中的应用

引用次数: 0

Acute Myeloid Leukemia 急性髓性白血病

Journal of the advanced practitioner in oncology

Pub Date : 2019-03-01 DOI: 10.6004/jadpro.2019.10.2.17

L. Lyle, Pa-C

Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. AML manifests by fever, pallor, anemia, hemorrhages and recurrent infections.

引用次数: 878

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the advanced practitioner in oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀